Tegaserod Stimulates 5-HT4 Serotonin Receptors in the Isolated Human Atrium
Open Access
- 17 October 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (20) , 11133
Abstract
Tegaserod (1-{[(5-methoxy-1H-indol-3-yl)methyliden]amino}-3-pentylguanidine) is a potent agonist at human recombinant 5-HT4 serotonin receptors. Consequently, tegaserod is utilized in the treatment of bowel diseases. The objective of this study was to test the hypothesis that tegaserod stimulates human cardiac atrial 5-HT4-receptors via cyclic adenosine monophosphate (cAMP)-dependent pathways. Tegaserod exerted positive inotropic effects (PIEs) and positive chronotropic effects (PCEs) in isolated left and right atrial preparations, respectively, from mice with cardiac-specific overexpression of the human 5-HT4 serotonin receptor (5-HT4-TG) in a concentration- and time-dependent manner. However, no effect was observed in the hearts of littermates of wild-type mice (WT). Western blot analysis revealed that the expression of 5-HT4 receptors was significantly higher in 5-HT4-TG mice compared to WT mice. The specificity of the signal for the 5-HT4 receptor was confirmed by the absence of the signal in the hearts of 5-HT4 receptor knockout mice. Furthermore, tegaserod increased the force of contraction (at concentrations as low as 10 nM), reduced the time of tension relaxation, and increased the rate of tension development in isolated electrically stimulated (at a rate of 60 beats per minute) human right atrial preparations (HAPs, obtained during open-heart surgery) when administered alone. The potency and efficacy of tegaserod to raise the force of contraction were enhanced in the presence of cilostamide, a phosphodiesterase III inhibitor. The positive inotropic effect of tegaserod in HAPs was found to be attenuated by the 5-HT4 serotonin receptor antagonist GR 125487 (0.1 µM). The efficacy of tegaserod (10 µM) in raising the force of contraction in HAPs was less pronounced than that of serotonin (10 µM) or isoprenaline (1 µM). Tegaserod shifted the concentration–response curve of the force of contraction to serotonin to the right in HAPs, indicating that it is a partial agonist at 5-HT4 serotonin receptors in this model. We propose that the mechanism of action of tegaserod in HAPs involves cAMP-dependent phosphorylation of cardiac regulatory proteins.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (PO732)
This publication has 36 references indexed in Scilit:
- Cardiovascular effects of bufotenin on human 5-HT4 serotonin receptors in cardiac preparations of transgenic mice and in human atrial preparationsNaunyn-Schmiedeberg's Archives of Pharmacology, 2023
- Cardiovascular effects of cisapride and prucalopride on human 5-HT4 receptors in transgenic miceNaunyn-Schmiedeberg's Archives of Pharmacology, 2018
- Phosphorylation of phospholamban and troponin I through 5-HT4 receptors in the isolated human atriumNaunyn-Schmiedeberg's Archives of Pharmacology, 2008
- The in vitro pharmacological profile of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activityNaunyn-Schmiedeberg's Archives of Pharmacology, 2008
- Functional serotonin 5-HT4 receptors in porcine and human ventricular myocardium with increased 5-HT4 mRNA in heart failureNaunyn-Schmiedeberg's Archives of Pharmacology, 2004
- First Pharmacokinetic—Pharmacodynamic Study in Humans with a Selective 5‐Hydroxytryptamine4 Receptor AgonistThe Journal of Clinical Pharmacology, 1997
- Do human atrial 5-HT4 receptors mediate arrhythmias?Trends in Pharmacological Sciences, 1994
- A 5-HT4-like receptor in human left atriumNaunyn-Schmiedeberg's Archives of Pharmacology, 1992
- A 5-HT4-like receptor in human right atriumNaunyn-Schmiedeberg's Archives of Pharmacology, 1991
- Piglet sinoatrial 5-HT receptors resemble human atrial 5-HT4-like receptorsNaunyn-Schmiedeberg's Archives of Pharmacology, 1990